ERBB2 and breast carcinoma: Clinically treatment of advanced breast cancer is faced with serious challenges, such as dormant micro-metastases, resistance to all systemic therapies, triple-negative breast cancer, genomic chaos, and transformed ER- and HER2-positive breast cancer.